Altimmune's intranasal COVID-19 vaccine shows sterilizing potential

By The Science Advisory Board staff writers

May 10, 2021 -- Preclinical data for Altimmune's intranasal AdCOVID vaccine candidate show the drug has sterilizing immunity potential after a single dose.

Sterilizing immunity is considered critical for blocking transmission of the virus, the company said. Data came from a preclinical mouse study that showed a single dose of AdCOVID blocked virus uptake in vaccinated mice compared to unvaccinated counterparts.

Altimmune plans to release phase I data from an AdCOVID clinical trial in June. The trial is evaluating three dose levels of the vaccine, according to the firm.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.